DMD and Duchenne muscular dystrophy: Genome‐editing in stem cells holds promise for a more sustained gene repair therapy for the monogenic disorder Duchenne muscular dystrophy (DMD).[21] Improved muscle histology has been achieved 6–8 weeks after systemic delivery of AAV9‐Cas9 in a dog model of DMD;[22] however, long‐term (1 year) dystrophin protein restoration via AAV8/9‐Cas9 genome‐editing in adult mdx mice led to humoral and cellular immune responses as well as induced unwanted off‐target effects, which requires further studies.[23]